ReviewFrontiers in medicine2021
Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 2 syntheses or guidelines pooled it, 221 citations in OpenAlex.
- Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Metabolomic Phenotype of Hepatic Steatosis and Fibrosis in Mexican Children Living with Obesity.Medicina (Kaunas, Lithuania) · 2023Trial
- Epidemiological and Clinical-Laboratorial Profile of Schistosomiasis in an Endemic Urban Area in Pernambuco, Brazil.Acta parasitologica · 2026Article
- The monoacylglycerol acyltransferase 2 inhibitor VB-85387 reduces MASLD.Journal of lipid research · 2026Article
- miR-34a and miR-223 as diagnostic biomarkers for the severity of non-alcoholic fatty liver disease.Journal, genetic engineering & biotechnology · 2026Article
- Inflammation burden index as a complementary marker for the assessment of hepatic steatosis and fibrosis: evidence from NHANES 2017-2018.Abdominal radiology (New York) · 2026Article
- Dendrobium officinale Polysaccharides Protected against CClChinese journal of integrative medicine · 2026Article
- A deep learning pipeline for liver macromolecular proton fraction quantification without subject-specific B1 acquisition using spin-lock MRI.Quantitative imaging in medicine and surgery · 2026Article
- A Transformer-Residual Network-Integrated Deep Learning Model for Digital Pathology-Based Grading and Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Liver Fibrosis.Clinical and translational gastroenterology · 2026Article
- Prognostic value of combined FIB-4 and AFP in predicting survival after hepatectomy for hepatocellular carcinoma: a multicenter cohort study.BMC cancer · 2026Article
- Real-World Insights in Designing SteatoStat: An End-to-End Deep Learning Pipeline for Hepatic Steatosis Quantification.Diagnostics (Basel, Switzerland) · 2026Article
- Western diet-induced MASH in PWK/PhJ mice identifies disruptions in amino acid and sphingolipid metabolism contributing to cardiac dysfunction.Nature communications · 2026Article
- Purification and Transcriptomic Characterization of Hypertrophied Hepatic Stellate Cells From CDAHFD Mouse Liver.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- MRI Quantification of Liver Fibrosis Using Diamagnetic Susceptibility: An Ex Vivo Validation Study.Tomography (Ann Arbor, Mich.) · 2026Article
- Thermoacoustic Ultrasound Assessment of Liver Steatosis-A Novel Approach for MASLD Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
- From Hematoxylin and Eosin to Masson's Trichrome: A Comprehensive Framework for Virtual Stain Transformation in Chronic Liver Disease Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
- Artificial intelligence‑based quantitative analysis of hepatic fibrosis in carbon tetrachloride-induced mouse model of metabolic dysfunction-associated steatohepatitis.Toxicological research · 2026Article
- Spatially resolved multiplex protein profiling reveals DNA methylation-dependent microenvironmental remodeling in liver fibrosis.PNAS nexus · 2026Article
- Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals.World journal of hepatology · 2026Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing percentage of people have or are at risk to develop non-alcoholic fatty liver disease (NAFLD) worldwide. NAFLD comprises different stadia going from isolated steatosis to non-alcoholic steatohepatitis (NASH). NASH is a chronic state of liver inflammation that leads to the transformation of hepatic stellate cells to myofibroblasts. These cells produce extra-cellular matrix that results in liver fibrosis. In a normal situation, fibrogenesis is a wound healing process that preserves tissue integrity. However, sustained and progressive fibrosis can become pathogenic. This process takes many years and is often asymptomatic. Therefore, patients usually present themselves with end-stage liver disease e.g., liver cirrhosis, decompensated liver disease or even hepatocellular carcinoma. Fibrosis has also been identified as the most important predictor of prognosis in patients with NAFLD. Currently, only a minority of patients with liver fibrosis are identified to be at risk and hence referred for treatment. This is not only because the disease is largely asymptomatic, but also due to the fact that currently liver biopsy is still the golden standard for accurate detection of liver fibrosis. However, performing a liver biopsy harbors some risks and requires resources and expertise, hence is not applicable in every clinical setting and is unsuitable for screening. Consequently, different non-invasive diagnostic tools, mainly based on analysis of blood or other specimens or based on imaging have been developed or are in development. In this review, we will first give an overview of the pathogenic mechanisms of the evolution from isolated steatosis to fibrosis. This serves as the basis for the subsequent discussion of the current and future diagnostic biomarkers and anti-fibrotic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.